Novartis Q2 2026: sales rise as earnings slip | NVS SEC Filing
Novartis Second Quarter and Half Year 2026 Condensed Interim Financial Report – Supplementary Data INDEX Page OPERATING PERFORMANCE…
Novartis CEO eyes 2026 growth despite record patent cliff
Novartis CEO Vas Narasimhan is doubling down on a growth forecast for 2026, even as the Swiss drugmaker’s…
Novartis Reports High Operating Margins Following Innovative Drugs Pivot
Novartis AG reported a significant transformation into a high-margin innovative medicines company in early 2026 following the successful…
Lilly raises stakes in Novartis battle with Verzenio data
Armed with new survival data from the monarchE trial of CDK4/6 inhibitor Verzenio, Eli Lilly looks set to…